
Synerkine Pharma BV secures EUR 12.1m in Series A extension
The Series A extension was led by Flerie with participation of existing investor Thuja Capital and new investors InnovationQuarter Capital and...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...

Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie has become the latest big pharma company to target the hot antibody-drug conjugate market, acquiring ImmunoGen and its Elahere ADC for...

Aboleris Pharma bags €27.3m in Series A Financing
AbolerIS Pharma SA’s financing was led by Caixa Capital Risc and co-led by Sound Bioventures and existing investor Newton Biocapital with...

microRNA could offer a safe target in atherosclerosis
The researcher demonstrateded that targeting of miR-206-3p with an experimental compound safely reversed the onset of atherosclerosis in a...

Solar Foods raises €8m in Series B financing
Solar Foods Oy has raised €8m (US$8.8m) from retail investors in Finland. The Series B round was led by Finland’s Springvest Oy, existing...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...